Enhanced oncolytic potency of replicative adenovirus expressing p53

Drug Resistance Updates

Volumn 6, Issue 1, 2003, Pages 5-7

  Nemunaitis, John ^a,b   Cunningham, Casey ^a   Senzer, Neil ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b Collins Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ONYX 015; PROTEIN P53; VIRUS PROTEIN;

ADENOVIRUS; ADENOVIRUS VECTOR DELTA 24 P53; ANTINEOPLASTIC ACTIVITY; DNA VIRUS; GENE; GENE DELIVERY SYSTEM; GENE P53; GENE TARGETING; HERPES SIMPLEX VIRUS; NOTE; OPEN READING FRAME; PRIORITY JOURNAL; TRANSGENE; UBIQUITINIZATION; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE; VIRUS RECOMBINANT; VIRUS REPLICATION;

EID: 0037303746     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-7646(02)00142-5     Document Type: Note

References (27)

1. Agarvala, S.S., Van Osterom, A., Petruzulli, G., et al., 1998. Phase I study of rad/p53 in patients with advanced head and neck cancer (HNC). Proc. ASCO 7, 384a (abstract 1470).
2. Borst, P., Borst, J., Smets, L.A., 2001. Does resistance to apoptosis affect clinical response to antitumor drugs? Drug Resist. Updates 4, 129-131.
3. Chen, P.H., Ornelles, D.A., Shenk, T., 1993. The adenovirus L3 23-kilodalton proteinase cleaves the amino-terminal head domain from cytokeratin 18 and disrupts the cytokeratin network of HeLa cells. J. Virol. 67, 3507-3514.
4. Clayman, G., El-Naggar, A.K., Lippman, S.M., et al., 1998. Adenoviral-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J. Clin. Oncol. 16, 2221-2232.
5. Fojo, T., 2002. P53 as a therapeutic target: unresolved issues on the road to cancer therapy targeting mutant p53. Drug Resist. Updates 5, 209-216.
6. Gomella, L.G., Mastranelo, M.J., McCue, P.A., Maguire, Jr., H.C., Mulholand, S.G., Lattime, E.C., 2001. Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J. Urol. 166, 1291-1295.
7. Haviv, Y.S., Takayama, K., Glasgow, J.N., et al., 2002. A model system for the design of armed replicating adenovirus using p53 as a candidate transgene. Mol. Ther. 1, 321-328.
8. Hawkins, L.K., Hermiston, T.W., 2001. Gene delivery from the E3 region of replicating human adenovirus: Evaluation of the ADP region. Gene Ther. 8, 1131-1141.
9. Khuri, F., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I., Romel, L., Gore, M., Ironside, J., Geise, C., Randlev, B., Gillenwater, A., Bruso, P., Kaye, S., Ki Hong, W., Kim, D., 2000. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-FU in patients with recurrent head and neck cancer. Nat. Med. 6, 879-885.
10. Kucharzuk, J.C., Randazzo, B., Elshami, A.A., Sterman, D.H., Amin, K.A., Molnar-Kimber, K.L., Brown, M.S., Litsky, L.A., Frasher, N.W., Albelda, S.M., Kaiser, L.R., 1997. Use of a replication-restricted recombinant herpes virus to treat localized human malignancy. Cancer Res. 57, 466-471.
11. Mastrangelo, M.J., Maguire, Jr., H.C., Eisiniohr, L.C., et al., 2000. Intratumoral recombinant GM-CSF-encoding virus to package amplicons containing cytokine gene therapy vector in cancer, persistent transgene expression despite antibody generation. Cancer Gene Ther. 7, 663-670.
12. Nemunaitis, J., Cunningham, C., 2002. Emerging new therapies for chemotherapy-resistant cancer using adenoviral vectors. Drug Resist. Updates 5, 34-46.
13. Nemunaitis, J., Bier-Laning, C.M., Costenla-Figueiras, M., et al., 1999. Three Phase II trials of intratumoral injection with a replicationdeficient adenovirus carrying the p53 gene (Ad5CMV-p53) in patients with recurrent/refractory head and neck cancer. Proc. Am. Soc. Clin. Oncol. 18, 431a (abstract 1661).
14. Nemunaitis, J., Swisher, S.G., Timmons, T., et al., 2000. Adenoviral mediated p53 gene transfer in sequence with Cisplatin to tumors of patients with non-small cell lung cancer. J. Clin. Oncol. 18, 609-622.
15. Nemunaitis, J., Cunningham, C., Buchanan, A., Blackburn, A., Edelman, G., Maples, P., Netto, G., Tong, A., Randlev, B., Olson, S., Kim, D., 2001a. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther. 8, 746-759.
16. Nemunaitis, J., Khuri, F., Ganly, I., Arseneau, J., Posner, M., Vokes, E., et al., 2001b. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol. 19, 289-298.
17. Nemunaitis, J., Senzer, N., Cunningham, C., Dubensky, T.W., 2001c. Virus-mediated killing of cells that lack p53 activity. Drug Resist. Updates 4, 289-291.
18. Nemunaitis, J., Cunningham, C., Tong, A.W., Netto, G., Paulson, A.S., Rich, D., Blackburn, A., Sands, B., Gibson, B., Freeman, S., Randlev, B., in press. Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther.
19. Roninson, I.B., Broude, E.V., Chang, B.-D., 2001. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist. Updates 4, 303-313.
20. Roth, J.A., Nguyen, D., Lawrence, D.D., et al., 1996. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat. Med. 2 (9), 985-999.
21. Swisher, S.G., Roth, J.A., Nemunaitis, J., et al., 1998. Adenoviral-mediated p53 gene transfer in patients with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 17, 431a (abstract 1659).
22. Tollefson, A.E., Scaria, A., Hermiston, T.W., et al., 1996. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J. Virol. 70, 2296-2306.
23. Toyozuimi, T., Mick, R., Abbas, A.E., Kang, E.H., Kaiser, L.R., Molnar-Kimber, K,L., 1999. Combined therapy with chemotherapeutic agents and herpes simplex virus type-1 ICP34.5 mutant (HSC-1716) in human non-small lung cancer. Hum. Gene Ther. 10, 3013-3029.
24. Van Beusechem, V.W., van den Doel, P.B., Grill, J., Pinedo, H.M., Gerritsen, W.R., 2002. Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res. 62, 6165-6171.
25. White, E., Cipriani, T., 1989. Specific disruption of intermediate filaments and the nuclear lamina by the 19-kDa product of the adenovirus E1B oncogene. Proc. Natl. Acad. Sci. U.S.A. 86, 9886-9890,
26. White, E., Cipriani, T., 1990. Role of adenovirus E1B proteins in transformation: altered organization of intermediate filaments in transformed cells that express the 19-kilodalton protein. Mol. Cell Biol. 10, 120-130.
27. Zhang, Y., Schneider, R.J., 1994. Adenovirus inhibition of cell translation facilitates release of vius particles and enhances degradation of the cytokeratin network. J. Virol. 68, 2544-2555.